CClinicalTrials.gg
Status unknownNCT02516800Updated May 9, 2017

Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD

An observational study in Aortic Valve Calcification and Aortic Stenosis, sponsored by University of Aarhus. Status unknown at 1 site in Denmark. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by University of Aarhus · Observational

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
600
Ages
Up to 65 Years
Sex
All
01

Study summary

Mutations in the SLC34A2 gene, that encodes the sodium phosphate co-transporter (NaPi-IIb), cause defect cell-uptake of phosphate, which leads to formation of calcium-phosphate concretions in the lungs as seen in Pulmonary Alveolar Microlithiasis (PAM). Extra pulmonary calcifications, including heart valve calcification, have previously been reported in patients with PAM.

Calcific Aortic Valve Disease (CAVD) is a common disease in the elderly and is characterised by thickening and calcification of the aortic valve leaflets in the absence of rheumatic heart disease. CAVD is present in more than 25% of patients older than age 65 years and is associated with an increased risk of cardiovascular events. Currently, there is no effective therapy for the disease other than surgical aortic valve replacement. Both calcium and phosphate are the major components of calcific deposits in PAM and CAVD. Based on these preliminary findings, the investigators hypothesize that mutations in sodium phosphate co-transporters may play a role in both pulmonary and extra pulmonary calcifications.

Two studies will be performed: 1. A retrospective cross-sectional study including patients with an age ≤ 65 years with CAVD from Denmark and Örebro, will be carried out. Genetic association analysis will be performed to investigate the incidence of common variants in five genes representing sodium phosphate co-transporters (SLC34A1, SLC34A2, SLC34A3, SLC20A1, SLC20A2) compared to healthy controls. Associated genes will subsequently be sequenced to identify possible causal mutations. 2. In a prospective study, aortic valve tissue will be collected from patients with AS undergoing surgical valve replacement. Molecular characterisation of the transporters will be conducted by determining the level of specific mRNA and protein by RT-PCR/qPCR, and Western Blotting, respectively. The localisation and visualisation will be investigated by immunostaining and confocal laser microscopy. Fibroblasts and endothelial cells will be isolated and grown in cultures with subsequent functional studies of the phosphate uptake.

02

Conditions studied

  • Aortic Valve Calcification
  • Aortic Stenosis

Browse trials for

03

In context

Aortic Valve Stenosis

985 studies on the registry are indexed under Aortic Valve Stenosis; 283 are open to participants now.

This study's planned enrollment of 600 is above the median of 200 across 424 observational studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with premature aortic valve stenosis in Denmark and Sweden.

Inclusion criteria

  • Aortic valve calcification
  • Informed consent before study participation
  • Age: ≥ 18 years ≤ 65 years

Exclusion criteria

Exclusion Criteria:

  • Lacking ability to give informed consent
  • Radiotherapy towards the thorax
  • Severe kidney disease (in dialysis)
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Aortic valve calcification

    Patients with calcific aortic valve disease, age = 65 years or below

  • Control group

    Matched control group

06

What researchers measure

Primary outcomes

  1. Frequencies of single-nucleotide polymorphisms in genes encoding NaPi co-transporters

    Time frame: Association analyses will be performed after 3 years

07

Study locations

1 of 1 sites recruiting
  • Department of Biomedicine, Aarhus University
    Aarhus, 8000, Denmark
    • Åsa Lina Alle Madsen, MD · Contact · jonsson@biomed.au.dk · +45 40513516
    • Åsa Lina Alle Madsen, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02516800
Lead sponsor
University of Aarhus
Responsible party
Sponsor
First posted
Aug 6, 2015
Start date
May 2014
Primary completion
Apr 2018 (estimated)
Completion
Apr 2019 (estimated)
Last update
May 9, 2017

Study contacts

Åsa Lina Alle Madsen, MD
Contact
jonsson@biomed.au.dk
+45 40513516
Ulf Simonsen, Professor
study chair · Department of Biomedicine, Aarhus University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion